Urothelial Carcinoma: Update on Staging and Reporting, and Pathologic Changes Following Neoadjuvant Chemotherapies

Manju Aron; Ming Zhou

doi:10.1016/j.path.2022.08.003

Urothelial Carcinoma: Update on Staging and Reporting, and Pathologic Changes Following Neoadjuvant Chemotherapies

Surg Pathol Clin. 2022 Dec;15(4):661-679. doi: 10.1016/j.path.2022.08.003. Epub 2022 Oct 13.

Authors

Manju Aron¹, Ming Zhou²

Affiliations

¹ Department of Pathology, Keck School of Medicine, University of Southern California; Department of Urology, Keck School of Medicine, University of Southern California. Electronic address: manjuaro@med.usc.edu.
² Department of Anatomic and Clinical Pathology, Tufts University School of Medicine and Tufts Medical Center, 800 Washington St., Box 802, Boston, MA 02111.

PMID: 36344182
DOI: 10.1016/j.path.2022.08.003

Abstract

Staging and reporting of cancers of the urinary tract have undergone major changes in the past decade to meet the needs for improved patient management. Substantial progress has been made. There, however, remain issues that require further clarity, including the substaging of pT1 tumors, grading and reporting of tumors with grade heterogeneity, and following NAC. Multi-institutional collaborative studies with prospective data will further inform the accurate diagnosis, staging, and reporting of these tumors, and in conjunction with genomic data will ultimately contribute to precision and personalized patient management.

Keywords: AJCC staging; Bladder; Grading; Neoadjuvant chemotherapy; Pathologic staging; Reporting; Urinary tract; Urothelial carcinoma.

Publication types

Review

MeSH terms

Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / pathology
Humans
Neoadjuvant Therapy
Neoplasm Staging
Prospective Studies
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology